CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to improve cancer treatment by developing innovative nano-sized vaccine carriers that target dendritic cells and T cells directly in the body. By utilizing new techniques to activate the immune system, it seeks to enhance the effectiveness of dendritic cell immunotherapy and eliminate the need for com…
Tumour cells survive and grow because they are not effectively recognized by the immune system as ¿foreign¿ and are therefore not attacked and destroyed like most pathogens.
We have already demonstrated the clinical value of dendritic cell (DC) vaccines that activate the immune system to fight cancer.
Treating more than 300 patients with metastatic melanoma, we achieved extended survival in 40% of patients by maturing dendritic cells from the patient¿s blood in-vitro, loading them with cancer-sp…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
